Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Current Deferred Revenue (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Current Deferred Revenue for 5 consecutive years, with $2.3 million as the latest value for Q2 2019.

  • Quarterly Current Deferred Revenue rose 5.8% to $2.3 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Jun 2019, up 5.8% year-over-year, with the annual reading at $1.7 million for FY2018, 43.69% down from the prior year.
  • Current Deferred Revenue for Q2 2019 was $2.3 million at Outlook Therapeutics, roughly flat from $2.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $3.1 million in Q3 2017, with the low at $1.2 million in Q3 2016.
  • Average Current Deferred Revenue over 5 years is $2.0 million, with a median of $2.0 million recorded in 2015.
  • The sharpest move saw Current Deferred Revenue skyrocketed 154.63% in 2017, then plummeted 43.69% in 2018.
  • Over 5 years, Current Deferred Revenue stood at $2.0 million in 2015, then tumbled by 38.75% to $1.2 million in 2016, then surged by 126.82% to $2.8 million in 2017, then dropped by 13.0% to $2.4 million in 2018, then fell by 2.39% to $2.3 million in 2019.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.3 million, $2.3 million, and $2.4 million for Q2 2019, Q1 2019, and Q4 2018 respectively.